Short Interest Update on Juno Therapeutics (JUNO)

Juno Therapeutics (JUNO) : Traders are negative on Juno Therapeutics (JUNO), as it has 14.3% of short positions outstanding compared to its float. The total shorts have reduced by -972,910 shares, which is a -8.3% reduction. From Jul 29, 2016, to August 15, 2016, the shorts came down from,11,751,735 to 10,778,825 shares. While the daily trading volume of the stock is 1,556,233, there are 7 days remaining to cover the open short positions. The short interest indicates that the traders dont see a large downside in the stock from the current levels. The short interest information was released on Wednesday Aug 24th after the market close.

Juno Therapeutics (NASDAQ:JUNO): The stock opened at $33.40 on Wednesday but the bulls could not build on the opening and the stock topped out at $34.35 for the day. The stock traded down to $31.73 during the day, due to lack of any buying support eventually closed down at $31.83 with a loss of -4.64% for the day. The stock had closed at $33.38 on the previous day. The total traded volume was 1,869,668 shares.


In a related news, The Securities and Exchange Commission has divulged that Klausner Richard, director of Juno Therapeutics, Inc., had unloaded 12,000 shares at an average price of $40.71 in a transaction dated on June 24, 2016. The total value of the transaction was worth $488,520.

Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Junos product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Junos other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171), JCAR020: MUC-16 / IL-12, ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial as a treatment for various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of AML, myelodysplasic syndrome and chronic myeloid leukemia.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.